Impaired Glucose Tolerance Clinical Trial
Official title:
Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture
Impaired Glucose Tolerance (IGT) is an abnormal metabolic state following glucose metabolic steady state but prior to diabetes. IGT is an important stage during the progression of diabetes, with an underlying mechanism of insulin resistance and pancreatic β cell dysfunction. IGT is one of the diseases that shows significant beneficial response to acupuncture treatment. Original findings from the investigators'laboratory show that transcutaneous auricular vagus nerve stimulation (taVNS) which is innervated by vagus nerve, would enhance the activity of pancreatic β cells, promote the secretion of insulin, upregulate the expression of insulin receptors in central as well as peripheral tissues, thus to improve glycometabolism. In this study, the investigators would further illuminate the mechanism of taVNS at "yidan-pi" auricular acupoints on the regulation of glucose metabolism, its improvement of the IGT state in rat model, as well as its regulation effect on insulin receptor expression and insulin resistance, and systematically illustrate the clinical effective of this treatment on IGT, with emphasize on its influence on the concentrations of glucose and HbA1c, and thus provide an effective proposal for clinical acupuncture.
Status | Not yet recruiting |
Enrollment | 158 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility |
Inclusion Criteria: - ages between 20 and 70 - fasting plasma-glucose(FPG) less than 7 mmol/L, or 2h p-glucose 7.8-11.1 mmol/L - anti-diabetic medication of any kind - able to provide informed consent Exclusion Criteria: - comorbidities that would prohibit participation in study procedures, including cardiovascular disease, hematological system disease or psychosis - females of childbearing potential who were pregnant, breast-feeding - infection within the 1 month - known or suspected abuse of alcohol or narcotics |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
China Academy of Chinese Medical Sciences |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | pulse | Normal pulse should be more than 60 per minute, or less than 100 per minute. | Baseline and 12 weeks | |
Other | respiration | Normal respiration should be more than 16 times, or less than 20 times. | Baseline and 12 weeks | |
Other | blood pressure | The systolic pressure should be no more than 139 mmHG, and the diastolic pressure should be no less than 89 mmHg. | Baseline and 12 weeks | |
Other | body temperature | Normal temperature should be more than 36 C, or less than 37 C. | Baseline and 12 weeks | |
Primary | FPG | The fasting plasma glucose (FPG) is used to diagnose diabetes. IGT can be diagnosed base on FPG less than 7.0 mmol/L. | Baseline and 6 week, 12 weeks | |
Primary | OGGT | The 2-hour plasma glucose after a 75-g oral glucose tolerance test (OGTT) is used to diagnose diabetes. IGT can be diagnosed base on 2-hour plasma Glucose between 7.8 and 11.1 mmol/L. | Baseline and 6 week, 12 weeks | |
Secondary | BMI | The body mass index are used to diagnose Obesity. Weight and height will be combined to report BMI in kg/m^2 | Baseline and 12 weeks | |
Secondary | A1C | The hemoglobin A1C (A1C) is a diagnostic test for diabetes. Diabetes can be diagnosed base on A1C more than 6.5%. | Baseline and 6 week,baseline and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT04088461 -
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
|
Phase 4 | |
Completed |
NCT02621060 -
Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
|
Phase 2 | |
Completed |
NCT01488279 -
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
|
N/A | |
Completed |
NCT01521312 -
ACute and Chronic Effects of Saxagliptin
|
Phase 2 | |
Completed |
NCT01559896 -
Egg Protein Hydrolysate and Vascular Function
|
N/A | |
Completed |
NCT01030978 -
Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program
|
N/A | |
Completed |
NCT00573781 -
Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism
|
Phase 2 | |
Terminated |
NCT00846521 -
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
|
Phase 4 | |
Completed |
NCT00241072 -
Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
|
Phase 4 | |
Completed |
NCT00536250 -
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
|
N/A | |
Completed |
NCT02254317 -
Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance
|
N/A | |
Completed |
NCT03764423 -
Health Effects of Salmon Fishmeal in Humans
|
N/A | |
Recruiting |
NCT05347030 -
Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population
|
N/A | |
Active, not recruiting |
NCT04341571 -
Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.
|
Phase 2 | |
Completed |
NCT02700334 -
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
|
Phase 4 | |
Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
Completed |
NCT02135172 -
Breaks in Sedentary Time and Glucose Regulation in Women
|
N/A | |
Active, not recruiting |
NCT01841229 -
Effect of Ginseng on Glycemic Control
|
N/A | |
Completed |
NCT02248272 -
Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes
|
N/A |